NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) LT-Debt-to-Total-Asset : 0.12 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NovaBay Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.12.

NovaBay Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2022 (0.10) to Dec. 2023 (0.12). It may suggest that NovaBay Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

NovaBay Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for NovaBay Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals LT-Debt-to-Total-Asset Chart

NovaBay Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.01

0.10

0.12

NovaBay Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.09	0.10	0.12

NovaBay Pharmaceuticals LT-Debt-to-Total-Asset Calculation

NovaBay Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.108	/	9.034
	=	0.12

NovaBay Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	1.108	/	9.034
	=	0.12

NovaBay Pharmaceuticals (AMEX:NBY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NovaBay Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

B9P:Germany

Address

2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608

Website

https://www.novabay.com

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Executives

Tommy Law	officer: Interim CFO	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin	officer: President, DERMAdoctor, LLC	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin	officer: Chief Product Officer	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall	officer: General Counsel	5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng	director	NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov	director	2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones	officer: CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu	director	SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu	10 percent owner	LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu	officer: NEO - Sr Mgr and Controller	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit	director	95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng	director	1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang	director	2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh	officer: Interim CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd	10 percent owner	FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000